# Vir Biotechnology

**Canonical:** https://apis.io/providers/vir-biotechnology/  
**Website:** http://vir.bio  
**APIs profiled:** 0

Vir Biotechnology is a clinical-stage immunology company that engineers antibodies into medicines targeting serious infectious diseases and cancer. Its programs span chronic hepatitis delta, hepatitis B, oncology, and prior work on COVID-19 and Ebola, built on a next-generation antibody platform and the licensed PRO-XTEN protease-releasable masking technology. Surfaced as a portfolio company of GV and added to the API Evangelist network. This is a corporate/investor-facing life-sciences company; enrichment probes found no public developer, API, or partner-integration surface.

## Kin Score — 3.3 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 3.3).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 7.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Security (1)

- **Vir Biotechnology Domain Security** — TLSv1.3 · HSTS · DMARC

## Tags

Company, Life Sciences, Biotechnology, Immunology, Pharmaceuticals, Antibodies, Infectious Disease, Oncology

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/vir-biotechnology/). Scores are computed from the provider's own public artifacts under a published rubric.